0001209191-15-070308.txt : 20150911
0001209191-15-070308.hdr.sgml : 20150911
20150911152005
ACCESSION NUMBER: 0001209191-15-070308
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150909
FILED AS OF DATE: 20150911
DATE AS OF CHANGE: 20150911
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Q Therapeutics, Inc.
CENTRAL INDEX KEY: 0001366541
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 203708500
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 615 ARAPEEN DRIVE
STREET 2: SUITE 102
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84108
BUSINESS PHONE: (801) 582-5400
MAIL ADDRESS:
STREET 1: 615 ARAPEEN DRIVE
STREET 2: SUITE 102
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84108
FORMER COMPANY:
FORMER CONFORMED NAME: Q Holdings, Inc.
DATE OF NAME CHANGE: 20111208
FORMER COMPANY:
FORMER CONFORMED NAME: Grace 2, Inc.
DATE OF NAME CHANGE: 20060619
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BORST STEVEN JOHN
CENTRAL INDEX KEY: 0001532620
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-52062
FILM NUMBER: 151103304
MAIL ADDRESS:
STREET 1: PO BOX 58154
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84158
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2015-09-09
0
0001366541
Q Therapeutics, Inc.
[NONE]
0001532620
BORST STEVEN JOHN
C/O Q THERAPEUTICS, INC.
615 ARAPEEN DRIVE, SUITE 102
SALT LAKE CITY
UT
84108
1
1
0
0
Chief Executive Officer
Option to Purchase Common Stock
0.70
2015-09-09
4
A
0
400000
0.70
A
2016-09-08
2025-09-08
Common Stock
400000
2536674
D
Option to Purchase Common Stock
0.70
2015-09-09
4
A
0
100000
0.70
A
2025-09-08
Common Stock
100000
2636674
D
Option to Purchase Common Stock
0.70
2015-09-09
4
A
0
100000
0.70
A
2025-09-08
Common Stock
100000
2736674
D
Option shall vest at the rate of 28% on the one year anniversary of the grant date and 2% per month thereafter.
Option will vest in full upon the closing of an equity and/or debt financing in the cumulative amount of $10 million on or prior to June 30, 2016.
Option to vest in full upon the first patient dosed in the Company's Phase I clinical trial.
Steven J. Borst
2015-09-11